Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retosiban - GlaxoSmithKline

Drug Profile

Retosiban - GlaxoSmithKline

Alternative Names: 221149; GSK-221149; GSK-221149A

Latest Information Update: 04 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Indenes; Morpholines; Oxazoles; Piperazines; Small molecules; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Preterm labour

Most Recent Events

  • 02 Sep 2019 GlaxoSmithKline completes the phase III ARIOS trial in Preterm labour in France, Spain, Belgium, Germany, Israel, Italy, Japan, Mexico, South Korea, Sweden, United Kingdom and USA (IV) (NCT02292784)
  • 24 Jun 2018 Biomarkers information updated
  • 20 Oct 2017 GlaxoSmithKline terminates a phase III trial in Preterm labour in Israel, Belgium, Germany, South Korea, Italy, Spain, Sweden, France, Mexico due to feasibility of recruiting the study in a timely manner (IV) (NCT02292771)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top